Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?

Viaene, Liesbeth; Behets, Geert J.; Claes, Kathleen; Meijers, Björn; Blocki, Franck; Brandenburg, Vincent; Evenepoel, Pieter; D’Haese, Patrick C.

doi:10.1093/ndt/gft039

Cited by 109 publications

(117 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lower sclerostin serum levels were identified as independent determinants of VC in patients with chronic kidney disease not yet on dialysis, thus it was suggested that circulating sclerostin may be a protective factor for the progression of VC (35). Consistent with this, higher sclerostin levels have been associated with a reduced mortality in hemodialysis patients (36).…”

Section: Clinical Studymentioning

confidence: 82%

“…A reduced bone formation as a consequence of reduced osteoblast activity has been identified as the mean pathogenetic effect or for low bone mineral density (BMD) in subjects with T1DM (1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39). intimal thickening in atherosclerosis, and Wnt/b-catenin signaling is a regulator of VSMC behavior (9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus

Catalano

Pintaudi

Morabito

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: Sclerostin is an osteocyte-derived inhibitor of the Wnt/b-catenin signaling pathway, which acts as a negative regulator of bone formation. Published data on sclerostin levels in type 1 diabetes mellitus (T1DM) are few. Objective: To evaluate gender differences in sclerostin serum levels and the association among sclerostin, bone mass, bone metabolism, and the main clinical characteristics of subjects with T1DM. Design and methods: A total of 69 patients with T1DM (mean age, 33.7G8.1; 49% males) were enrolled in this cross-sectional study in a clinical research center. Bone mineral density was measured by phalangeal quantitative ultrasound (QUS); bone turnover markers (urinary pyridinoline, deoxypyridinoline (D-PYR), and urine hydroxyproline (OH-PRO) to evaluate bone resorption; serum bone alkaline phosphatase and BGP to evaluate bone formation) and sclerostin were assessed. Results: D-PYR and sclerostin were significantly higher in women when compared with men (PZ0.04). A disease duration

show abstract

Section: Clinical Studymentioning

confidence: 82%

Section: Introductionmentioning

confidence: 99%

Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus

Catalano

Pintaudi

Morabito

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Viaene et al [50] showed that in patients on haemodialysis, the serum concentration of sclerostin is higher than in general population. In the future, these data will be repeatedly confirmed by the results of other studies devoted to identify the role of sclerostin in patients on regular haemodialysis [23,49].…”

Section: The Relation Of Fgf-23 Klotho and Sclerostin With Cardiovasmentioning

confidence: 99%

Disorders in the System of Mineral and Bone Metabolism Regulators—FGF-23, Klotho and Sclerostin—in Chronic Kidney Disease: Clinical Significance and Possibilities for Correction

Milоvаnоvа¹,

Fоmin²,

Lysenko³

et al. 2018

Chronic Kidney Disease - From Pathophysiology to Clinical Improvements

View full text Add to dashboard Cite

The chapter discusses the current understanding of the system of mineral and bone metabolism regulators-FGF-23, Klotho and sclerostin-disturbances in chronic kidney disease (CKD). In the chapter we presented the date, including our own results, which allow to suggest the change in the ratio of FGF-23-Klotho-sclerostin in CKD as an early biomarker not only for the chronic kidney damage but also for high cardiovascular (CV) risk. Results of studies show that disorders in FGF-23-Klotho-sclerostin ratio correlate with the frequency and severity of hypertension, vascular calcification, cardiac remodelling, anaemia, malnutrition, inflammation and strong aggravate CV risk in CKD. It was found independent from blood pressure (BP) action of increased serum FGF-23 on the myocardium as well as the correlation of serum high-sensitive troponin I with increased serum FGF-23 and low Klotho levels in CKD patients. At the same time, it was shown that renoprotective therapy, including renin-angiotensin blockers, low-protein diet with amino/keto acid supplementation and phosphate binders, erythropoiesis stimulators, vitamin D metabolites used to get the target levels of BP, serum phosphorus, haemoglobin, parathyroid hormone and nutritional status disorders correction can reduce the risk of CV events, as the major cause of death in CKD patients.

show abstract

“…77 In hemodialysis patients, serum sclerostin levels were found to be inversely associated with mortality, 78 raising concerns about the long-term cardiovascular safety of sclerostin inhibition. Further investigation is needed in order to address this critical issue and shed more light on the potential effects of sclerostin on the vasculature.…”

Section: Discussionmentioning

confidence: 99%

The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosis

Yavropoulou

Xygonakis

Lolou

et al. 2014

View full text Add to dashboard Cite

Sclerosteosis and Van Buchem disease are two rare bone sclerosing disorders characterized by increased bone mineral density, tall stature and entrapment of cranial nerves due to overgrowth of a highly dense bone. Recent advances in human genetics have revealed the genetic background of these disorders by cloning the SOST gene, which is localized on chromosome region 17q12-q21 and codes for sclerostin. Sclerostin is a protein produced almost exclusively from osteocytes inhibiting bone formation by both osteoblasts and osteocytes. At the molecular level, sclerostin inhibits the Wnt signaling pathway, which plays a critical role in osteoblast development and function. Induced sclerostin deficiency in mice reproduces the bone sclerosing human diseases, while sclerostin excess leads to bone loss and reduced bone strength. The extracellular nature of sclerostin has rendered it a promising target for the development of novel anti-osteoporotic treatment. Otherwise healthy carriers of the SOST mutation present with increased bone mass and low levels of sclerostin in serum in contrast to patients with sclerosteosis, who exhibit undetectable levels, thus pointing to the possibility of titration of sclerostin levels in the circulation. Based on these unique characteristics, human anti-sclerostin antibodies have been developed and tested in ovariectomized rats and monkeys, demonstrating very promising results in bone formation. Clinical phase II and III trials are currently underway thereby translating human genetics to drug development.

show abstract

Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?

Abstract: Our data show that high circulating sclerostin levels are associated with improved survival and suggest that a low bsAP activity may be in the causal pathway.

Cited by 109 publications

References 41 publications

Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus

Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus

Disorders in the System of Mineral and Bone Metabolism Regulators—FGF-23, Klotho and Sclerostin—in Chronic Kidney Disease: Clinical Significance and Possibilities for Correction

The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosis

Contact Info

Product

Resources

About